• Capio Biosciences

Cancer Diagnostic Startup Capio Moves to Wisconsin, Raises $2.9M

Jeff Buchanan | January 5th, 2017

In certain patients who are being treated for cancer, it’s possible for cells to detach from the tumors inside their bodies and begin moving through the bloodstream.

These circulating tumor cells, or CTCs, can help oncologists and other clinicians determine how a disease is progressing, and how effective treatments given to that patient have been.

But getting this information requires capturing CTCs, which is not an easy task, in part because CTCs are so rare. That’s according to Seungpyo Hong, a professor at the University of Wisconsin-Madison School of Pharmacy. He is also the co-founder of Capio Biosciences,


Need more details? Contact us.


We are here to assist. If you require further information or are interested in collaborations or partnerships, contact us by phone, email or via our social media channels.

  • White LinkedIn Icon
  • White Twitter Icon
  • White Facebook Icon

505 S. Rosa Road
Suite 10C
Madison, WI 53719


* The CapioCyte System is currently under development and not for use in diagnostic procedures.


Capio and CapioCyte are trademarks of Capio Biosciences.